Antibodies News and Research

RSS

In silico study suggests SARS-CoV-2 Omicron XBB.1.5 strain to be more infective than previous strains

Researchers performed an in silico analysis to estimate the relative risks of recently emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants.

23 Jan 2023

Study reviews mechanistic data on new methods of allergy prevention and treatment

In a recent article published in Science Translational Medicine, researchers reviewed the cause and the underlying pathophysiology of allergic diseases.

23 Jan 2023

What was the prevalence of adverse events following first and second dose COVID-19 vaccinations in England?

A recent Eurosurveillance study focused on estimating the incidence of a prespecified list of adverse events following the first and second doses of the COVID-19 vaccination.

23 Jan 2023

Potent small-molecule inhibitors against SARS-CoV, MERS-CoV, and SARS-CoV-2

In a recent study posted to bioRxiv* preprint server, researchers in the United States identified several potent pan-coronavirus (CoV) inhibitors.

23 Jan 2023

SARS-CoV-2 Omicron XBB.1.5, CA.3.1, and CH.1.1 exhibit remarkable antibody resistance

In a recent study posted to bioRxiv* preprint server, researchers at Ohio State University examined the degree of neutralizing antibody (nAb) evasion by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron XBB.1.5, CA.3.1, and CH.1.1 subvariants.

23 Jan 2023

Phase I trial results from AdaptVac's COVID capsid virus-like particle vaccine

In a recent study published in The Lancet Microbe journal, researchers described the effectiveness of a modular capsid virus-like coronavirus disease 2019 (COVID-19) vaccination.

22 Jan 2023

People with hybrid immunity are the most protected against severe COVID-19 and reinfection

A University of Calgary research group - which includes several Bachelor of Health Sciences alumni joined forces with members of the World Health Organization to tackle a global health question.

20 Jan 2023

Analysis of seemingly recovered COVID-19 patients indicates that SARS-CoV-2 infection can persist significantly longer than suggested by PCR-negative tests

Scientists have described the infection dynamics and clinical features of PCR-negative patients who eventually died due to the worsening of COVID-19.

20 Jan 2023

Longitudinal assessment of immunoglobulin G antibody responses to messenger ribonucleic acid vaccination doses and breakthrough infections

Researchers evaluated immunoglobulin G (IgG) responses to coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccinations.

20 Jan 2023

How effective are prior SARS-CoV-2 infections and hybrid immunity against Omicron breakthrough infections?

Researchers performed a systematic review and meta-regression study to determine the breadth and duration of the protective immunity conferred by previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and hybrid immunity.

20 Jan 2023

InDevR raises $9 million in series B financing and partners with bioMérieux

New partnerships will drive the commercial expansion of InDevR’s game-changing solutions for vaccines and biotherapeutics.

20 Jan 2023

Mutations may underlie how the most aggressive lymphomas arise and resist therapies

The key to understanding how the most aggressive lymphomas arise and resist current therapies may lie in mutations that disrupt a critical natural selection process among antibody-producing B cells, according to a multi-institutional preclinical study led by Weill Cornell Medicine investigators.

19 Jan 2023

Wistar scientists receive $397,663 to explore the ability of natural killer cells to kill HIV-infected cells

amfAR, The Foundation for AIDS Research, has awarded Luis J. Montaner, D.V.M., D.Phil., in collaboration with Mohamed Abdel-Mohsen, Ph.D., a Target Grant for $397,663 over two years. Montaner, who leads The Wistar Institute's HIV Research Program, is studying the ability of a type of immune cell known as natural killer (NK) cells to kill HIV-infected cells.

19 Jan 2023

Exploring the infectivity, transmissibility, and immunological resistance characteristics of SARS-CoV-2 Omicron XBB.1.5 strain

Researchers performed an epidemic dynamic analysis to assess the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC)’s sub-VOC XBB.1.5 characteristics.

19 Jan 2023

Researchers find that study results converge on a consistent relationship between antibody levels and protection from COVID-19

Researchers described the factors associated with protection, protection thresholds, and immunobridging in COVID-19 patients.

19 Jan 2023

How do mutations in emergent SARS-CoV-2 Omicron variants affect viral function, human immunity, and recognition by therapeutic antibodies?

Researchers explored how mutations in emergent SARS-CoV-2 variants affect viral function, human immunity, and recognition by therapeutic antibodies.

19 Jan 2023

Berkeley Lights launches Beacon Select™, a new optofluidic system for cell line development

Berkeley Lights, Inc., a life sciences tools company, today announced the launch of the Beacon Select™, the company's new optofluidic system for cell line development (CLD).

From Bruker Cellular Analysis 19 Jan 2023

T-cell immunity and antibody responses against SARS-CoV-2 among individuals registered in the Bangkok home health care service

Researchers performed an observational study among COVID-19 patients and their close contacts registered with the Bangkok home health care services in Thailand.

18 Jan 2023

Epitope mapping reveals the humoral responses against the main SARS-CoV-2 structural proteins in infected patients from Africa

Researchers performed immunoglobulin (Ig)M and IgG epitope mapping against 487 SARS-CoV-2 peptides.

18 Jan 2023

Study sheds new light on how the B cell academy mounts a diverse immune response

Cells jostling for a spot in a germinal center face a cutthroat admissions process. Formed after exposure to a pathogen or vaccine, germinal centers act as a kind of immune system training academy, helping B cells refine their response to the threat.

18 Jan 2023

Antibodies News and Research

In silico study suggests SARS-CoV-2 Omicron XBB.1.5 strain to be more infective than previous strains

Study reviews mechanistic data on new methods of allergy prevention and treatment

What was the prevalence of adverse events following first and second dose COVID-19 vaccinations in England?

Potent small-molecule inhibitors against SARS-CoV, MERS-CoV, and SARS-CoV-2

SARS-CoV-2 Omicron XBB.1.5, CA.3.1, and CH.1.1 exhibit remarkable antibody resistance

Phase I trial results from AdaptVac's COVID capsid virus-like particle vaccine

People with hybrid immunity are the most protected against severe COVID-19 and reinfection

Analysis of seemingly recovered COVID-19 patients indicates that SARS-CoV-2 infection can persist significantly longer than suggested by PCR-negative tests

Longitudinal assessment of immunoglobulin G antibody responses to messenger ribonucleic acid vaccination doses and breakthrough infections

How effective are prior SARS-CoV-2 infections and hybrid immunity against Omicron breakthrough infections?

InDevR raises $9 million in series B financing and partners with bioMérieux

Mutations may underlie how the most aggressive lymphomas arise and resist therapies

Wistar scientists receive $397,663 to explore the ability of natural killer cells to kill HIV-infected cells

Exploring the infectivity, transmissibility, and immunological resistance characteristics of SARS-CoV-2 Omicron XBB.1.5 strain

Researchers find that study results converge on a consistent relationship between antibody levels and protection from COVID-19

How do mutations in emergent SARS-CoV-2 Omicron variants affect viral function, human immunity, and recognition by therapeutic antibodies?

Berkeley Lights launches Beacon Select™, a new optofluidic system for cell line development

T-cell immunity and antibody responses against SARS-CoV-2 among individuals registered in the Bangkok home health care service

Epitope mapping reveals the humoral responses against the main SARS-CoV-2 structural proteins in infected patients from Africa

Study sheds new light on how the B cell academy mounts a diverse immune response

Antibodies eBook

Deciphering the Microbiome with The Microsetta Initiative

Leveraging the power of automation to boost research

Automating research - solutions and best practices

Latest Life Science News